Docoh
Loading...

CYAN Cyanotech

Cyanotech Corp. engages in the development and commercialization of natural products derived from microalgae. Its products include BioAstin natural astaxanthin, a dietary antioxidant shown to support and maintain the body's natural inflammatory response, to enhance skin, and to support eye and joint health; and Spirulina Pacifica, a dietary supplement used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. The company was founded by Gerald R. Cysewski in 1983 and is headquartered in Kailua-Kona, HI.

Company profile

CYAN stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

11 Feb 21
22 Apr 21
31 Mar 22
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Mar 20 Mar 19 Mar 18 Mar 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Cyanotech earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 3.32M 3.32M 3.32M 3.32M 3.32M 3.32M
Cash burn (monthly) 310.33K (positive/no burn) (positive/no burn) (positive/no burn) 74K (positive/no burn)
Cash used (since last report) 1.16M n/a n/a n/a 276.85K n/a
Cash remaining 2.16M n/a n/a n/a 3.05M n/a
Runway (months of cash) 7.0 n/a n/a n/a 41.2 n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
6 Apr 21 Cysewski Gerald R Common Stock Payment of exercise Dispose F No No 3.35 13 43.55 137,087
6 Apr 21 Cysewski Gerald R Common Stock Option exercise Aquire M No No 0 33 0 137,100
6 Apr 21 Cysewski Gerald R RSU Common Stock Option exercise Dispose M No No 0 33 0 2,802
6 Apr 21 Jensen Glenn Common Stock Payment of exercise Dispose F No No 3.35 13 43.55 17,916
6 Apr 21 Jensen Glenn Common Stock Option exercise Aquire M No No 0 33 0 17,929
6 Apr 21 Jensen Glenn RSU Common Stock Option exercise Dispose M No No 0 33 0 2,262
6 Apr 21 Johansen Jennifer M. Common Stock Payment of exercise Dispose F No No 3.35 13 43.55 1,878
6 Apr 21 Johansen Jennifer M. Common Stock Option exercise Aquire M No No 0 33 0 1,891
6 Apr 21 Johansen Jennifer M. RSU Common Stock Option exercise Dispose M No No 0 33 0 1,996
6 Apr 21 Nordin Amy Beth Common Stock Option exercise Aquire M No No 0 33 0 727

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

11.3% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 9 10 -10.0%
Opened positions 0 0
Closed positions 1 0 NEW
Increased positions 2 4 -50.0%
Reduced positions 2 2
13F shares
Current Prev Q Change
Total value 2.09M 1.69M +23.7%
Total shares 687.39K 689.98K -0.4%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
WFC Wells Fargo & Co. 375.17K $1.14M 0.0%
Renaissance Technologies 182.13K $554K +9.3%
Coastline Trust 82.4K $250K 0.0%
MS Morgan Stanley 14.84K $45K 0.0%
Heritage Investors Management 13.79K $42K 0.0%
BLK Blackrock 11.57K $35K 0.0%
Tower Research Capital 2.79K $8K +890.8%
BAC Bank Of America 2.5K $8K -34.2%
NTRS Northern Trust 2.2K $7K -1.8%
Proequities 0 $0
Largest transactions
Shares Bought/sold Change
California Public Employees Retirement System 0 -19.3K EXIT
Renaissance Technologies 182.13K +15.53K +9.3%
Tower Research Capital 2.79K +2.51K +890.8%
BAC Bank Of America 2.5K -1.3K -34.2%
NTRS Northern Trust 2.2K -41 -1.8%
WFC Wells Fargo & Co. 375.17K 0 0.0%
Proequities 0 0
MS Morgan Stanley 14.84K 0 0.0%
Heritage Investors Management 13.79K 0 0.0%
Coastline Trust 82.4K 0 0.0%

Financial report summary

?
Competition
Cardax
Management Discussion
  • Net Sales The net sales increased $1.7 million, or 5.6%, in the year ended March 31, 2020 compared with fiscal year 2019. This increase was primarily driven by a $2.2 million, or 68.0%, increase in both astaxanthin and spirulina bulk sales and an increase in contract extraction sales of $0.3 million, offset by $0.8 million, or 3.2%, decrease in packaged sales when compared with fiscal year 2019. The bulk sales increase was primarily the result of lack of product available for our bulk customers in the prior year. The decrease in packaged sales for astaxanthin was the result of non-recurring replenishment orders in fiscal year 2019, that were the result of depleted inventory related to the re-inoculation of our ponds. Contract extraction revenue more than doubled in the current year as we continue to grow this service to third-party producers of astaxanthin biomass.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: absorption, CAA, combination, comparison, constant, COVID, exclusion, extinguishment, freight, gain, idle, judgement, kilo, notice, overturn, permanent, Rev, Rul, spoilage, store, tourism, TRA